Literature DB >> 9528018

[Clinical-epidemiological characteristics of late onset multiple sclerosis].

A O Gómez-García1, O Fernández-Concepción, E Milán-Ginjauma.   

Abstract

INTRODUCTION: Multiple sclerosis (MS) is the most frequent demyelinating disorder of the central nervous system. It mainly affects young adults and it has been calculated that between 20% and 30% are of late onset (after the age of 40), presenting clinical features, a clinical course and prognosis which are specific to this disorder.
MATERIAL AND METHODS: Between 1985 and 1994 we studied 297 cases of MS (diagnosed according to the criteria of Poser) and found that in 20.5% the illness had started when the patients were over the age the 40. RESULTS AND
CONCLUSIONS: Certain aspects of the clinical features and course of the disorder were compared, taking the group of late onset cases and a randomized sample of 100 cases of early onset, showing that the symptoms and pyramidal signs were more frequent in the late onset group, whilst sensory and visual signs were commoner in the early onset group. In both groups there were more females. MS was defined according to Poser's criteria in 78.7% and 77% respectively. Chronic, primary and secondary progressive forms predominated in tire late onset group, whilst in the group with onset before the age of 40 there was a predominance of the exacerbating-remitting form.

Entities:  

Mesh:

Year:  1997        PMID: 9528018

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  3 in total

Review 1.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

2.  Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.

Authors:  Rachel Butler Pagnotti; Le H Hua; Justin B Miller
Journal:  Mult Scler       Date:  2021-08-19       Impact factor: 5.855

3.  Clinical characteristics of patients with late-onset multiple sclerosis.

Authors:  Bernhard Kis; Bastian Rumberg; Peter Berlit
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.